24 results about "Defensin" patented technology

The application provides a composite antibacterial peptide preparation, a preparation method and application. The composite antibacterial peptide preparation comprises a first defensin, a second defensin, a first cecropin and a second cecropin. The amino acid sequence of the first defensin is shown in SEQ ID NO:1, the amino acid sequence of the second defensin is shown in SEQ ID NO:2, the amino acid sequence of the first cecropin is shown in SEQ ID NO:3, and the amino acid sequence of the second cecropin is shown in SEQ ID NO:4. Compared with a single antibacterial peptide, the composite antibacterial peptide preparation has good stability, and shows good inhibitory effect on various gram-positive bacteria, gram-negative bacteria and fungi.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The application discloses a full-gorge hard tick-derived defensin polypeptide and application thereof. The defensin polypeptide is IpDf3, and the amino acid sequence is shown as SEQ ID NO:1. The defensin polypeptide has different degrees of antibacterial activity on four gram-positive bacteria and two gram-negative bacteria. Bactericidal kinetics and scanning electron microscope experiments show that 3*MIC IpDf3 can quickly down-regulate the bacterial number by 1-4 logarithmic units in 60 min, and can cause irregular bulges or depressions on the surface of gram-positive bacteria, and even rupture of the cell membrane, indicating that the antibacterial mechanism may be closely related to the direct damage of the cell membrane. The defensin polypeptide not only has the activity of traditional defensin against gram-positive bacteria, but also has certain antibacterial activity against gram-negative bacteria, has a wide antibacterial spectrum, strong activity, fast bactericidal speed, and is expected to provide a candidate for the research and development of new antibacterial drugs, and has important application prospects.

The application discloses a traditional Chinese medicine exosome compound with anti-HPV and application thereof, and relates to the technical field of biotechnology.The compound comprises functional components secreted by a human cell co-culture system and a traditional Chinese medicine source extract, and the traditional Chinese medicine source extract is derived from a combined traditional Chinese medicine extract of Astragalus membranaceus, Isatis indigotica Fort., Honeysuckle and Sophora flavescens Ait., and relates to the technical field of biotechnology.The traditional Chinese medicine exosome carries natural active ingredients, and a multi-target anti-virus network is formed by beta-defensin-2 and interferon-gamma generated by co-culture with human cells.Compared with single traditional Chinese medicine extract or chemically synthesized nanoparticles, the HPV inhibition rate is increased by more than 170%, and the direct cytotoxicity of traditional Chinese medicine is reduced through an exosome delivery system, and the IC 50 >200ug / mL, which is significantly lower than that of a water decoction, and mucous membrane irritation experiments show no damage.

Provided is a [beta]-defensin-3 mRNA expression promoter comprising dipotassium glycyrrhizinate.

The application discloses a preparation method of enteric sustained-release defensin mesoporous silica nanoparticles. The enteric sustained-release defensin mesoporous silica nanoparticles prepared by the method have good defensin loading capacity, good responsiveness to trypsin and good enteric targeting and sustained-release defensin performance.

The application discloses a pig beta-defensin-3 gene core promoter and a construction method and application thereof, and belongs to the technical field of genetic engineering. The sequence of the core promoter is shown as SEQ ID No. 1, the core promoter has significant promoter activity in pig small intestinal epithelial cells, and can be regulated by nutrients such as sodium butyrate and glutamine. The application also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: performing PCR amplification by taking pig small intestinal epithelial cell DNA as a template, taking the upstream primer and the downstream primer shown as SEQ No. 2-SEQ No. 3 as the primer, constructing a pMD-18T-pBD-3-P recombinant plasmid, and taking the recombinant plasmid as a template to amplify a core promoter fragment. The core promoter provides an excellent experimental system for studying the transcriptional regulation mechanism of the pig beta-defensin-3 gene, the nutrient response characteristics provide a new platform for studying the interaction between nutrition and immunity, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

Provided herein is an antimicrobial composition for hygiene applications. The antimicrobial composition comprises an effective concentration of a cathelicidin LL-37 peptide fragment in combination with an effective concentration of non- ionic surfactant. The non-ionic surfactant is an Alkyl-Poly Glucoside (APG) or alcohol ethoxylates or both. The antimicrobial composition further comprises of a chelating agent like disodium EDTA, or malic acid or citric acid or GLDA or PES A. The composition achieves log reduction of at least 3 against Gram negative bacteria Pseudomonas aeruginosa, Escherichia coll and Gram positive bacteria Staphylococcus aureus, Enterococcus hirae.

Antimicrobial defensin peptide variants comprising modified C-terminal fragments of a defensin and nucleic acids encoding the same are disclosed. Compositions comprising the defensin variant peptides and methods of their use to control microbial infections of plants and vertebrate subjects as well as contamination of feedstuffs and foodstuffs are also disclosed.

The present application provides a black soldier fly defensin C-13326, the nucleotide sequence of the black soldier fly defensin C-13326 is shown as SEQ ID NO.1, and the application of the black soldier fly defensin C-13326 in inhibiting multiple drug-resistant Aeromonas sobria is also provided.The black soldier fly defensin C-13326 provided by the present application can be applied to the preparation of anti-drug-resistant Aeromonas sobria products to cope with the serious harm caused by drug-resistant Aeromonas sobria.

The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity, said peptides for use in modulating the microbiome of the gut, lung, skin, mouth, eye, ear, vagina or other body surface, and / or as antimicrobial agents in humans or other mammals; and to medicaments containing these peptides.

The invention belongs to the technical field of mosquito-borne infectious disease prevention and control, and provides an effect of human defensin in inhibition of anopheles sterneri malarial. According to the invention, the human defensin 5 is injected into the body of the anopheles stellari model by adopting a method for constructing the anopheles stellari infection model, and the influence of the human defensin 5 on the malarial transmission capability of the anopheles stellari is evaluated. Results show that after entering the mosquito body, the human defensin 5 inhibits the development of plasmodium johnsonii in the anopheles stersonii at an early stage by stimulating the innate immunity of the mosquito, so that the purpose of reducing the malarial transmission capability of the anopheles stersonii is achieved.

The invention belongs to the field of polypeptides, and discloses an antibacterial peptide as well as a preparation method and application thereof. The antibacterial peptide is obtained by modifying the structure of the American oyster defensin derived peptide A4, and the antibacterial activity and stability of the original antibacterial peptide are further improved. Experiments prove that the antibacterial peptide disclosed by the invention has broad-spectrum antibacterial activity, and has good bacteriostatic activity on paratyphoid B and escherichia coli; pathogenic bacteria can be directly killed, and the effect is rapid; the hemolytic activity is low, the stability is relatively high, and the cytotoxicity is low. The antibacterial peptide provided by the invention is stable in preparation method and high in synthesis efficiency. The antibacterial peptide provided by the invention can be used as a therapeutic molecule for various common infections, and solves the increasingly serious problem of antibiotic drug resistance at present.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to beta-defensin produced by Chinese softshell turtles as well as a coding gene and application of the beta-defensin. In order to provide the novel antibacterial peptide, the amino acid sequence of the beta-defensin produced by the Chinese softshell turtle is shown as SEQ NO.2, and the nucleotide sequence of the coding gene of the beta-defensin is shown as SEQ NO.1.

Clostridium difficile, reclassified as Clostridioides difficile, is a Gram-positive, spore-forming, anaerobic, and toxin-producing nosocomial pathogen. Since the first description of a C. difficile-associated disease (CDAD)-like case in 1892, C. difficile infection (CDI) has become a high-impact health care-associated infection throughout the world, especially in the developed countries. Described herein are methods of treating Clostridium difficile infection in a subject in need thereof by administering an amount of the engineered lysin-human defensin (LHD) protein(s) described herein.

Antimicrobial modified defensin or defensin-like peptides, modified C-terminal fragments of defensins or defensin-like peptides, and nucleic acids encoding them are disclosed. Compositions containing the defensin mutant peptides and methods of using them to control microbial infections in plants and vertebrates, and to control feed and food contamination are also disclosed.

The invention discloses an engineered PVC protein compound for targeted removal of intracellular staphylococcus aureus as well as a preparation method and application of the engineered PVC protein compound, and belongs to the fields of genetic engineering, microbiology and drug delivery. Genetic engineering modification is carried out on PVC, a natural recognition domain of tail fiber protein of the PVC is replaced by a staphylococcus aureus receptor binding structural domain (SRapid BR), and meanwhile, natural toxin protein loaded in an inner cavity of the PVC is replaced by human beta-defensin-3 (HBD-3) with efficient bactericidal activity. The engineered compound can directly deliver HBD-3 into infected cells, effectively remove intracellular staphylococcus aureus which is difficult to kill by conventional antibiotics, and relieve inflammatory response caused by infection. The invention provides a brand-new treatment strategy for resisting intracellular bacterial infection with high targeting, and shows a wide application prospect as a programmable protein delivery platform.

Disclosed is use of starch for providing benefit selecting from the group consisting of inducing secretion of anti-microbial peptide, protecting from microbial infection, improving barrier function boosting innate defense, upregulating the gene expression of cathelicidin antimicrobial peptide or the gene expression of human beta-defensin-4.

The invention discloses an application of a CD2 antagonist in preparation of an antituberculous drug. The preparation method comprises the following steps: targeting CD2 molecules on the surface of an NK cell by virtue of a high-affinity CD2 antagonist, synergistically strengthening the degranulation of the NK cell and the release of antibacterial peptide (granulysin, beta-defensin 4), and directly destroying the completeness of a cell membrane and a cell wall of mycobacterium tuberculosis (Mtb), so that the extracellular rapid sterilization is realized; in an in-vitro NK cell-macrophage co-culture model, the number of intracellular CFUs is remarkably reduced through the strategy; meanwhile, the mitochondrial membrane potential and metabolic activity of the NK cells are optimized, and the lasting effect is maintained; in a peripheral blood model of a tuberculosis patient, the strategy significantly amplifies Mtb-induced infected macrophage death, reduces intracellular bacterial load, integrally improves the ability of immune cells to remove infected macrophages, and provides a safe, efficient and convertible molecular intervention entry point for precise immunotherapy of tuberculosis, especially multidrug-resistant tuberculosis.

This invention relates to the field of antimicrobial peptide technology, and particularly to the antimicrobial peptide Ple-AB, its preparation method, and its applications. Using the fungal defensin Plectasin as a template, this invention designs and modifies the antimicrobial peptide Ple-AB. Compared with Plectasin, this antimicrobial peptide exhibits significantly higher antimicrobial activity and better bactericidal effects against Gram-positive bacteria; it also shows higher stability, particularly excellent resistance to trypsin; and its fermentation expression level is significantly improved. Furthermore, this antimicrobial peptide has very low hemolytic activity and cytotoxicity, making it suitable for development in antimicrobial drugs, additives, cosmetics, health products, and other fields, with broad application value and market prospects.

To provide a defensin expression promoter having an excellent defensin expression promoting action on the skin or in vivo.SOLUTION: Lysophosphatidic acid or its salt is used as an active ingredient. Since lysophosphatidic acid or a salt thereof has an excellent defensin expression promoting action on the skin or in vivo, it can be preferably used for the purpose of improving the antibacterial action on the skin or in vivo. It is particularly effective for promoting the expression of human β - defensin-1 and human β - defensin-3 among defensins. In addition, since lysophosphatidic acid or a salt thereof also has an action of suppressing proliferation of Propionibacterium acnes based on the action of promoting expression of human β - defensin-3, it can be used as an agent for suppressing proliferation of Propionibacterium acnes.SELECTED DRAWING: None

Compositions and methods of using defensin peptides and proteins are provided, including folded variants of antibacterial defensin peptides and proteins (DEFPFV) that exhibit advantageous antifungal properties and desirable resistance or sensitivity to protease cleavage that can be applied directly ex vivo to plants, humans, or animals, such as, for example, plants, humans, or animals. Or can be applied in vivo to plants, humans or animals.

This invention belongs to the field of plant genetic engineering technology, and specifically discloses defensin-like substances. BrTI2 Application of genes in controlling lead accumulation from atmospheric deposition sources in Chinese cabbage leaves. This invention is the first to discover a defensin-like substance with a nucleotide sequence as shown in SEQ ID No. 1. BrTI2 This gene is closely related to the lead content in Chinese cabbage leaves under atmospheric deposition lead stress. It can mediate the biosynthesis of cell wall components in Chinese cabbage leaves, promoting cell wall thickening, thereby reducing the influx of atmospheric deposition lead into the leaf symptom, and ultimately lowering the lead accumulation level in Chinese cabbage leaves. This invention provides important theoretical support for molecular precision breeding of low-lead-accumulation Chinese cabbage, targeted control of the ecological effects of atmospheric deposition lead, and the realization of green and safe production of Chinese cabbage, and has significant application value and social benefits.

Compositions are provided for formulations of θ-defensin and / or a θ-defensin analog that are highly suitable for parenteral administration. Such formulations provide the θ-defensin and / or a θ-defensin analog in a slightly acidic buffer that includes propylene glycol. Surprisingly, Inventors have found that such formulation increase bioavailability of a θ-defensin and / or a θ-defensin analog so provided by at least a factor of 10 relative to conventional isotonic saline solutions, and that such formulations dramatically improved bioavailability in human subjects relative to animal models. Inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, reducing injection volume permitting sterilization by simple filtration.